La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.

Identifieur interne : 000093 ( Ncbi/Checkpoint ); précédent : 000092; suivant : 000094

In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.

Auteurs : C S Lee [Canada] ; A. Samii ; V. Sossi ; T J Ruth ; M. Schulzer ; J E Holden ; J. Wudel ; P K Pal ; R. De La Fuente-Fernandez ; D B Calne ; A J Stoessl

Source :

RBID : pubmed:10762161

English descriptors

Abstract

Clinical symptoms of Parkinson's disease (PD) do not manifest until dopamine (DA) neuronal loss reaches a symptomatic threshold. To explore the mechanisms of functional compensation that occur in presynaptic DA nerve terminals in PD, we compared striatal positron emission tomographic (PET) measurements by using [11C]dihydrotetrabenazine ([11C]DTBZ; labeling the vesicular monoamine transporter type 2), [11C]methylphenidate (labeling the plasma membrane DA transporter), and [18F]dopa (reflecting synthesis and storage of DA). Three consecutive PET scans were performed in three-dimensional mode by using each tracer on 35 patients and 16 age-matched, normal controls. PET measurements by the three tracers were compared between subgroups of earlier and later stages of PD, between drug-naive and drug-treated subgroups of PD, and between subregions of the parkinsonian striatum. The quantitative relationships of [18F]dopa and [11]DTBZ, and of [11C]methylphenidate and [11C]DTBZ, were compared between the PD and the normal control subjects. We found that [18F]dopa Ki was reduced less than the binding potential (Bmax/Kd) for [11C]DTBZ in the parkinsonian striatum, whereas the [11C]methylphenidate binding potential was reduced more than [11C]DTBZ binding potential. These observations suggest that the activity of aromatic L-amino acid decarboxylase is up-regulated, whereas the plasma membrane DA transporter is down-regulated in the striatum of patients with PD.

PubMed: 10762161


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:10762161

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.</title>
<author>
<name sortKey="Lee, C S" sort="Lee, C S" uniqKey="Lee C" first="C S" last="Lee">C S Lee</name>
<affiliation wicri:level="1">
<nlm:affiliation>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre, British Columbia, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Samii, A" sort="Samii, A" uniqKey="Samii A" first="A" last="Samii">A. Samii</name>
</author>
<author>
<name sortKey="Sossi, V" sort="Sossi, V" uniqKey="Sossi V" first="V" last="Sossi">V. Sossi</name>
</author>
<author>
<name sortKey="Ruth, T J" sort="Ruth, T J" uniqKey="Ruth T" first="T J" last="Ruth">T J Ruth</name>
</author>
<author>
<name sortKey="Schulzer, M" sort="Schulzer, M" uniqKey="Schulzer M" first="M" last="Schulzer">M. Schulzer</name>
</author>
<author>
<name sortKey="Holden, J E" sort="Holden, J E" uniqKey="Holden J" first="J E" last="Holden">J E Holden</name>
</author>
<author>
<name sortKey="Wudel, J" sort="Wudel, J" uniqKey="Wudel J" first="J" last="Wudel">J. Wudel</name>
</author>
<author>
<name sortKey="Pal, P K" sort="Pal, P K" uniqKey="Pal P" first="P K" last="Pal">P K Pal</name>
</author>
<author>
<name sortKey="De La Fuente Fernandez, R" sort="De La Fuente Fernandez, R" uniqKey="De La Fuente Fernandez R" first="R" last="De La Fuente-Fernandez">R. De La Fuente-Fernandez</name>
</author>
<author>
<name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D B" last="Calne">D B Calne</name>
</author>
<author>
<name sortKey="Stoessl, A J" sort="Stoessl, A J" uniqKey="Stoessl A" first="A J" last="Stoessl">A J Stoessl</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2000">2000</date>
<idno type="RBID">pubmed:10762161</idno>
<idno type="pmid">10762161</idno>
<idno type="wicri:Area/PubMed/Corpus">001645</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001645</idno>
<idno type="wicri:Area/PubMed/Curation">001645</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001645</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001645</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001645</idno>
<idno type="wicri:Area/Ncbi/Merge">000093</idno>
<idno type="wicri:Area/Ncbi/Curation">000093</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000093</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.</title>
<author>
<name sortKey="Lee, C S" sort="Lee, C S" uniqKey="Lee C" first="C S" last="Lee">C S Lee</name>
<affiliation wicri:level="1">
<nlm:affiliation>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre, British Columbia, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre, British Columbia</wicri:regionArea>
<wicri:noRegion>British Columbia</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Samii, A" sort="Samii, A" uniqKey="Samii A" first="A" last="Samii">A. Samii</name>
</author>
<author>
<name sortKey="Sossi, V" sort="Sossi, V" uniqKey="Sossi V" first="V" last="Sossi">V. Sossi</name>
</author>
<author>
<name sortKey="Ruth, T J" sort="Ruth, T J" uniqKey="Ruth T" first="T J" last="Ruth">T J Ruth</name>
</author>
<author>
<name sortKey="Schulzer, M" sort="Schulzer, M" uniqKey="Schulzer M" first="M" last="Schulzer">M. Schulzer</name>
</author>
<author>
<name sortKey="Holden, J E" sort="Holden, J E" uniqKey="Holden J" first="J E" last="Holden">J E Holden</name>
</author>
<author>
<name sortKey="Wudel, J" sort="Wudel, J" uniqKey="Wudel J" first="J" last="Wudel">J. Wudel</name>
</author>
<author>
<name sortKey="Pal, P K" sort="Pal, P K" uniqKey="Pal P" first="P K" last="Pal">P K Pal</name>
</author>
<author>
<name sortKey="De La Fuente Fernandez, R" sort="De La Fuente Fernandez, R" uniqKey="De La Fuente Fernandez R" first="R" last="De La Fuente-Fernandez">R. De La Fuente-Fernandez</name>
</author>
<author>
<name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D B" last="Calne">D B Calne</name>
</author>
<author>
<name sortKey="Stoessl, A J" sort="Stoessl, A J" uniqKey="Stoessl A" first="A J" last="Stoessl">A J Stoessl</name>
</author>
</analytic>
<series>
<title level="j">Annals of neurology</title>
<idno type="ISSN">0364-5134</idno>
<imprint>
<date when="2000" type="published">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Aged</term>
<term>Carbon Radioisotopes</term>
<term>Carrier Proteins (metabolism)</term>
<term>Corpus Striatum (diagnostic imaging)</term>
<term>Corpus Striatum (metabolism)</term>
<term>Dopamine (metabolism)</term>
<term>Dopamine Plasma Membrane Transport Proteins</term>
<term>Down-Regulation (physiology)</term>
<term>Fluorine Radioisotopes</term>
<term>Homovanillic Acid (metabolism)</term>
<term>Humans</term>
<term>Membrane Glycoproteins</term>
<term>Membrane Transport Proteins</term>
<term>Middle Aged</term>
<term>Nerve Tissue Proteins</term>
<term>Parkinson Disease (diagnostic imaging)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Presynaptic Terminals (metabolism)</term>
<term>Tetrabenazine (analogs & derivatives)</term>
<term>Tomography, Emission-Computed</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en">
<term>Tetrabenazine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Carrier Proteins</term>
<term>Dopamine</term>
<term>Homovanillic Acid</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en">
<term>Carbon Radioisotopes</term>
<term>Dopamine Plasma Membrane Transport Proteins</term>
<term>Fluorine Radioisotopes</term>
<term>Membrane Glycoproteins</term>
<term>Membrane Transport Proteins</term>
<term>Nerve Tissue Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en">
<term>Corpus Striatum</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Corpus Striatum</term>
<term>Parkinson Disease</term>
<term>Presynaptic Terminals</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Down-Regulation</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Aged</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Tomography, Emission-Computed</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Clinical symptoms of Parkinson's disease (PD) do not manifest until dopamine (DA) neuronal loss reaches a symptomatic threshold. To explore the mechanisms of functional compensation that occur in presynaptic DA nerve terminals in PD, we compared striatal positron emission tomographic (PET) measurements by using [11C]dihydrotetrabenazine ([11C]DTBZ; labeling the vesicular monoamine transporter type 2), [11C]methylphenidate (labeling the plasma membrane DA transporter), and [18F]dopa (reflecting synthesis and storage of DA). Three consecutive PET scans were performed in three-dimensional mode by using each tracer on 35 patients and 16 age-matched, normal controls. PET measurements by the three tracers were compared between subgroups of earlier and later stages of PD, between drug-naive and drug-treated subgroups of PD, and between subregions of the parkinsonian striatum. The quantitative relationships of [18F]dopa and [11]DTBZ, and of [11C]methylphenidate and [11C]DTBZ, were compared between the PD and the normal control subjects. We found that [18F]dopa Ki was reduced less than the binding potential (Bmax/Kd) for [11C]DTBZ in the parkinsonian striatum, whereas the [11C]methylphenidate binding potential was reduced more than [11C]DTBZ binding potential. These observations suggest that the activity of aromatic L-amino acid decarboxylase is up-regulated, whereas the plasma membrane DA transporter is down-regulated in the striatum of patients with PD.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Canada</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D B" last="Calne">D B Calne</name>
<name sortKey="De La Fuente Fernandez, R" sort="De La Fuente Fernandez, R" uniqKey="De La Fuente Fernandez R" first="R" last="De La Fuente-Fernandez">R. De La Fuente-Fernandez</name>
<name sortKey="Holden, J E" sort="Holden, J E" uniqKey="Holden J" first="J E" last="Holden">J E Holden</name>
<name sortKey="Pal, P K" sort="Pal, P K" uniqKey="Pal P" first="P K" last="Pal">P K Pal</name>
<name sortKey="Ruth, T J" sort="Ruth, T J" uniqKey="Ruth T" first="T J" last="Ruth">T J Ruth</name>
<name sortKey="Samii, A" sort="Samii, A" uniqKey="Samii A" first="A" last="Samii">A. Samii</name>
<name sortKey="Schulzer, M" sort="Schulzer, M" uniqKey="Schulzer M" first="M" last="Schulzer">M. Schulzer</name>
<name sortKey="Sossi, V" sort="Sossi, V" uniqKey="Sossi V" first="V" last="Sossi">V. Sossi</name>
<name sortKey="Stoessl, A J" sort="Stoessl, A J" uniqKey="Stoessl A" first="A J" last="Stoessl">A J Stoessl</name>
<name sortKey="Wudel, J" sort="Wudel, J" uniqKey="Wudel J" first="J" last="Wudel">J. Wudel</name>
</noCountry>
<country name="Canada">
<noRegion>
<name sortKey="Lee, C S" sort="Lee, C S" uniqKey="Lee C" first="C S" last="Lee">C S Lee</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000093 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 000093 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:10762161
   |texte=   In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i   -Sk "pubmed:10762161" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1 

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022